Abstract
In the preceding paper we have demonstrated an increase in presentation of both major histocompatibility complex antigens (MHC) and a tumor-associated antigen of the weakly immunogenic B16 melanoma by a straight-forward technique. The method consists in modulating the tumor cell membrane by hydrostatic pressure and simultaneous chemical crosslinking of the cell-surface proteins. In B16-BL6 melanoma, the induced antigenic modulation was found to persist for over 48 h, which permitted the evaluation of the ability of modified B16-BL6 cells to induce immunity against unmodified B16-BL6 cells. In the present study, we have shown that a significant systemic immunity was induced only in mice that were immunized with modified B16-BL6 melanoma cells, whereas immunization with unmodified B16-BL6 cells had only a marginal effect when compared to the results in control sham-immunized mice. The induced immunity was specific since a single immunization affected the growth of B16-BL6 tumors but had no effect on MCA 106, an antigenically unrelated tumor. The addition of interleukin-2 to the immunization regimen had no effect on the antitumor responses induced by the modified B16-BL6 cells. The cell-mediated immunity conferred by immunization with treated B16-BL6 cells was confirmed in experiments in vitro where splenocytes from immunized mice could be sensitized to proliferate by the presence of B16-BL6 cells. In addition, the altered antigenicity of these melanoma cells appeared to correlate with their increased susceptibility to specific effectors. Thus,51Cr-labeled B16-BL6 target cells, modified by pressure and crosslinking, in comparison to control labeled target cells, were lysed in much greater numbers by effectors such as lymphokine-activated killer cells and allogeneic cytotoxic lymphocytes (anti-H-2b), while such cells remained resistant to lysis by natural killer cells. Our findings indicate that the physical and chemical modifications of the tumor cells that are described here may be considered as a simple yet effective method for the preparation of tumor vaccines, which could be applied in tumor-bearing hosts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barth RJ, Bock SN, Mule JJ, Rosenberg SA (1990) Unique murine tumor associated antigens identified by tumor infilrating lymphocytes. J Immunol 144: 1531
Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC (1987) The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329: 512
Bosslet K, Schirrmacher V, Schantz G (1979) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice: VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytotoxic T cells in vitro. Int J Cancer 24: 303
Darrow TL, Slingluff CL, Siegler HF (1989) Role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: Evidence for shared tumor antigens. J Immunol 142: 3329
Doyle A, Martin J, Funa K, Gazdar A, Carney D, Martin SE, Linnoila I, Cuttia F, Mulshine J, Bunn P, Minna J (1985) Markedly decreased expression of class I histocompatibility antigens, protein and mRNA in human small cell lung cancer. J Exp Med 161: 1135
Festenstein H, Schmidt W (1981) Variation in MHC antigenic profiles of tumor cells and its biological effects. Immunol Rev 60: 85
Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T (1984) The role of tumor specific Lyt1+ T cells in eradicating tumor cells in vivo. J Immunol 133: 1671
Herberman RB (1986) Natural killer cells. Annu Rev Med 37: 347
Holden CA, Sanderson AR, McDonald DM (1983) Absence of human leukocyte antigens in skin tumors and some cutaneous appendages: evidence using monoclonal antibodies. J Am Acad Dermatol 9: 867
Itoh K, Platsoucas CD, Balch CM (1988) Autologous tumor specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin-2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 168: 1419
Key ME, Talmadge JE, Fogler WE, Bucana D, Fidler IJ (1982) Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl peptide. JNCI 69: 1189
Lafreniere R, Rosenberg SA (1986) A novel approach to the generation and identification of experimental hepatic metastases in a murine model. JNCI 76: 309
Lampson LA, Fisher CA, Whelan JP (1983) Striking paucity of HL-A, B, C and β2 microglobulin on human neuroblastoma cell lines. J Immunol 130: 2471
Mule JJ, Yang JC, Shu S, Rosenberg SA (1986) The anti-tumor efficacy of lymphokine activated killer cells and recombinant interleukin-2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 136: 3389
Papa MZ, Mule JJ, Rosenberg SA (1986) Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and non-immunogenic murine tumors of three histological types. Cancer Res 46: 4973
Ralph P, Nakoinz I, Rennick D (1988) Role of interleukin 2, interleukin 4, and α, β, and γ interferon in stimulating macrophage antibody-dependent tumoricidal activity. J Exp Med 167: 712
Ramakrishna V, Shinitzky M (1991) Potentiation of delayed type hypersensitivity response to syngeneic tumors in mice prevaccinated with tumor cells modified by hydrostatic pressure and crosslinking. Cancer Immunol Immunother 33: 1
Ramakrishna V, Eisenthal A, Skornick Y, Shinitzky M (1992) Increased projection of MHC and tumor antigen in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical corsslinking. Cancer Immunol Immunother 36: 293–299
Rosenberg SA (1988) Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9: 58
Rosenberg SA, Spiess P, Lafreniere R (1988) A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233: 1318
Russell SW, Mackintosh AT (1977) Macrophages isolated from Moloney sarcomas are more cytotoxic than those recovered from progressive sarcomas. Nature 268: 69
Spiess PJ, Yang JC and Rosenberg SA (1987) In vivo activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2. JNCI 79: 1067
Tanaka K, Hayashi H, Hamada C, Khoury C, Jay G (1986) Expression of major histocompatibility complex I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci USA 83: 8723
Topalian SL. Solomon D, Rosenberg SA (1989) Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714
Travers PJ, Arklie JL, Trowsdale J, Patillo RA, Bodmer WF (1982) Lack of expression of HLA, B, C antigens in choriocarcinoma and other human tumor cell lines. NCI Monogr 60: 175
Weber JS, Jay G, Tanaka K, Rosenberg SA (1987) Immunotherapy of murine tumor with interleukin-2. Increased sensitivity after MHC class I gene transfection. J Exp Med 166: 1716
Wood GW, Gillespie GY (1975) Studies on the role of macrophages in regulation of growth and metastasis of murine chemically induced fibrosarcoma. Int J Cancer 16: 1022
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenthal, A., Ramakrishna, V., Skornick, Y. et al. Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking. Cancer Immunol Immunother 36, 300–306 (1993). https://doi.org/10.1007/BF01741168
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01741168